Keith joined EyeBio as Vice President of Clinical Development in 2023. He is responsible in this capacity for the strategy and execution of EyeBio’s clinical research programs across its portfolio.
As a comprehensive ophthalmologist, Keith has over 20 years of clinical and industry experience in ophthalmology. Most recently, Keith served as Executive Medical Director at Gyroscope Therapeutics, where he led Medical Affairs for the GT005 development program in Geographic Atrophy. Prior to Gyroscope, Keith served in multiple positions of increasing responsibility at Regeneron Pharmaceuticals, beginning with the successful launch of EYLEA in 2012.
Keith is a graduate of Duke University, Dartmouth (Geisel) Medical School, and the Amos Tuck School of Business at Dartmouth College. He completed his ophthalmology residency training at the University of North Carolina Hospitals in Chapel Hill, NC, where he also served as Chief Resident.
